STJ

1,159.75

-2.38%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,159.75

-2.38%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,159.75

-2.38%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,159.75

-2.38%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,159.75

-2.38%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

Strona główna・Stock List・GlaxoSmithKline PLC

GlaxoSmithKline PLC

Closed

SectorHealthcare

1,858.5 -0.83

Buy Sell

Overview

Share price change

24h

Current

Min

1855.25

Max

1864.25

Key metrics
By Trading Economics
Income	1.2B 1.8B
Sales	-989M 7.6B
P/E Sector Avg	12.989 51.415
EPS	0.465
Dividend yield	3.64
Profit margin	24.105
Employees	66,841
EBITDA	577M 2.8B

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+6.11% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	3.64% 2.34%
Next Earnings	29 lip 2026
Next Dividend date	9 lip 2026
Next Ex Dividend date	13 sie 2026

Market Stats
By TradingEconomics
Market Cap	-6.4B 74B
Previous open	1859.33
Previous close	1858.5

News Sentiment

By Acuity

58%

42%

260 / 345 Ranking in Healthcare

GlaxoSmithKline PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 06:42 UTC

Earnings

GSK Earnings Boosted by Higher Specialty Medicine Sales

6 maj 2026, 13:35 UTC

Market Talk

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

29 kwi 2026, 10:39 UTC

Market Talk

Acquisitions, Mergers, Takeovers

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

29 kwi 2026, 10:06 UTC

Market Talk

Earnings

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 kwi 2026, 10:02 UTC

Market Talk

Earnings

GSK Makes Ideal Start for New CEO -- Market Talk

29 kwi 2026, 06:07 UTC

Earnings

GSK PLC Sees 70p 2026 Dividend Payout

29 kwi 2026, 06:07 UTC

Earnings

GSK PLC Declares Dividend of 17p

29 kwi 2026, 06:07 UTC

Earnings

GSK PLC Free Cash Flow of GBP0.8B

29 kwi 2026, 06:06 UTC

Earnings

GSK PLC Cash Generated From Operations GBP1.4B

29 kwi 2026, 06:06 UTC

Earnings

GSK PLC 1Q General Medicines Sales GBP2.3B

29 kwi 2026, 06:06 UTC

Earnings

GSK PLC 1Q Vaccines Sales GBP2.1B

29 kwi 2026, 06:06 UTC

Earnings

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

29 kwi 2026, 06:05 UTC

Earnings

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

29 kwi 2026, 06:04 UTC

Earnings

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

29 kwi 2026, 06:04 UTC

Earnings

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

29 kwi 2026, 06:04 UTC

Earnings

Analysts Saw GSK PLC Core EPS of 43.3p

29 kwi 2026, 06:04 UTC

Earnings

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

29 kwi 2026, 06:04 UTC

Earnings

GSK PLC 1Q Adj EPS 46.50p

29 kwi 2026, 06:01 UTC

Earnings

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

29 kwi 2026, 06:01 UTC

Earnings

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

29 kwi 2026, 06:01 UTC

Earnings

GSK PLC Sees 2026 Turnover Growth of 3%-5%

29 kwi 2026, 06:01 UTC

Earnings

GSK PLC Backs 2026 View

29 kwi 2026, 06:00 UTC

Earnings

GSK PLC 1Q EPS 42.6p

29 kwi 2026, 06:00 UTC

Earnings

GSK PLC 1Q Turnover GBP7.63B

29 kwi 2026, 06:00 UTC

Earnings

GSK PLC 1Q Pretax Pft GBP2.14B

29 kwi 2026, 06:00 UTC

Earnings

GSK PLC 1Q Oper Pft GBP2.29B

29 kwi 2026, 06:00 UTC

Earnings

GSK PLC 1Q Net Pft GBP1.74B

15 kwi 2026, 06:12 UTC

Acquisitions, Mergers, Takeovers

GSK Completes Acquisition of 35Pharma

10 kwi 2026, 10:43 UTC

Market Talk

GSK Could Report Weak General Medicines Results -- Market Talk

31 mar 2026, 14:02 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics Will Continue Supplying Products Previously Manufactured at Site to GSK Under Terms of Agreement

Peer Comparison

Price change

GlaxoSmithKline PLC Forecast

Price Target

By TipRanks

6.11% upside

12 Months Forecast

Average 1,976.36 GBX 6.11%

High 2,630 GBX

Low 1,500 GBX

Based on 13 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to GlaxoSmithKline PLC - Dist in the past 3 months.

Sentiment

By Acuity

260 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.